Theratechnologies inc.
TSX : TH

Theratechnologies inc.

October 09, 2007 17:15 ET

Theratechnologies Announces Acceptance of Late Breaker Abstract at the 11th European Aids Conference

MONTREAL, QUEBEC--(Marketwire - Oct. 9, 2007) - Theratechnologies (TSX:TH) today announced that its abstract entitled "Long-Term Safety and Efficacy of Tesamorelin (TH9507) a Growth Hormone-Releasing Factor Analogue in HIV-Infected Patients with Abdominal Fat Accumulation" was accepted as a late breaker presentation at the 11th European AIDS Conference, which will take place in Madrid, from October 24 to 27, 2007.

Dr. Steve Grinspoon, Associate Professor of Medicine, Harvard Medical School, Director of the Massachusetts General Hospital Program in Nutritional Metabolism, and Lead Investigator for the tesamorelin trial in the United States will take this opportunity to present additional data of the Phase 3 trial evaluating tesamorelin over 52 weeks. Dr. Grinspoon's presentation is scheduled on October 26, between 10:30 a.m. and 12:30 p.m., please visit www.theratech.com for updated schedule information.

"The acceptance of Theratechnologies' late breaker abstract reflects the importance of the positive results from tesamorelin's Phase 3 trial, as there is nothing currently approved for patients suffering from HIV-associated lipodystrophy," commented Dr. Christian Marsolais, Vice President, Clinical Research for Theratechnologies. "This trial is the largest one of its kind with greater than 400 patients participating for a 52-week period and we are elated to be able to present our long-term safety and efficacy data at one of the most well recognized AIDS conferences worldwide," continued Dr. Marsolais.

In addition to the late breaker presentation, Theratechnologies will hold a Satellite Symposium, entitled "Body Fat Changes and Metabolic Abnormalities in HIV: Facing the Challenge", at the European AIDS Conference, on October 26, 2007, from 7:30 to 9:00 a.m. The symposium's scientific program will include the following presentations:

- "Body Fat Changes and Metabolic Complications Associated with Antiretroviral Therapy", by Dr. Pere Domingo, Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;

- "Increased Cardiovascular Risk in HIV: Contribution of the Different Risk Factors ", by Dr. Jens D. Lundgren, Professor, University of Copenhagen, and Chief Physician and Head, Copenhagen HIV Program Hvidovre University Hospital, Denmark;

- "Clinical Management of Metabolic Complications", by Dr. Stefan Mauss, Co-founder, Center for HIV and Hepatogastroenterology, Dusseldorf, Germany;

- "Treatment Options and Strategies for Reducing Lipohypertrophy in HIV", by Dr. Steven Grinspoon, Associate Professor of Medicine, Harvard Medical School, Director of the Massachusetts General Hospital Program in Nutritional Metabolism, and Lead Investigator for the tesamorelin trial in the United States.

HIV-associated Lipodystrophy

HIV-associated lipodystrophy is characterized by a change in the distribution of adipose tissue (fat containing tissue), dyslipidemia and glucose intolerance. VAT accumulation with its concomitant metabolic profile is known to be a risk factor for cardiovascular diseases. The changes in fat distribution include visceral fat accumulation and/or loss of subcutaneous fat, generally in the limbs and in the face. There is no treatment available for the accumulation of visceral fat found in patients with HIV-associated lipodystrophy. It is estimated that approximately 250,000 HIV-infected patients in North America and Europe suffer an excessive accumulation of visceral fat.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, which has recently completed patient recruitment for its confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. Tesamorelin could be the first compound on the market to treat HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

About the European AIDS Conference

Organized by the European AIDS Clinical Society (EACS), a not-for-profit scientific society of European clinicians and researchers, the European AIDS Conference is the most comprehensive European HIV/AIDS meeting. It is held every two years in a different European city. The 12th European AIDS Conference will take place in 2009 in Cologne, Germany.

Contact Information